Vikram Anand
President, Compliance Services
专长:
Vikram’s experience includes more than 20 years of leading global teams and building successful partnerships with top life sciences companies and health authorities around the globe. He has a strong background in digital technology and business consulting across R&D including drug safety, clinical research, and regulatory compliance and reporting, as well as a deep understanding of the commercial landscape dealing with medical information and product complaints management. Vikram has worked directly with the top 50 global life sciences companies and industry authorities including the FDA, EMA, NOMA, PMDA, FIMEA, AFSSAPS, and Health Canada. At EVERSANA, Vikram’s Compliance team includes Medical Communications, Pharmacovigilance, Product and Medical Information Contact Center, and Regulatory and Quality Consulting and Outsourcing Services.
Vikram has authored numerous white papers and articles for national industry publications on the impact of emerging technologies on life sciences, including global regulatory reporting and security challenges of software-as-a service. He holds a Bachelor in Science Degree in Pharmacy from Punjabi University, a Master of Business Administration from Manipal University, and Post Graduate Diploma in Digital Strategies and Transformation from Columbia Business School/MIT Sloan.
Articles by Vikram Anand
WEBINAR: A Pivotal Shift in Life Sciences Industry Across R&D and Commercial: A Conversation with the Experts
The life sciences pipeline is evolving from small molecules to biologics and cell and gene therapy, and there are currently more than 900 therapies in clinical trials. As competition rises, manufacturers also need to manage the reality that the cost of research and development has doubled as ROI reduces from 10% to 2%. In this […]
Compliance – The Competitive Differentiator to Commercialization: An Integrated Model Setting the New Global Standard
The Compliance experts at EVERSANA prove how integrated life science compliance has earned its seat at the table by demonstrating the value of increasing data-driven and technology-infused competitiveness in the successful commercialization of a new-age biopharma product.